Assembly Biosciences (ASMB) Capital Expenditures (2011 - 2026)
Assembly Biosciences (ASMB) posted quarterly Capital Expenditures of $19000.0 for Q1 2026, down 20.83% quarter-over-quarter from $24000.0 in Q4 2025.
Assembly Biosciences (ASMB) Capital Expenditures (2011 - 2026) Analysis & Trends
Assembly Biosciences' Capital Expenditures history runs 16 years deep, the most recent figure standing at $19000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures changed N/A year-over-year to $19000.0; the TTM figure through Mar 2026 stood at $85000.0 (up 507.14% YoY), while the FY2025 annual figure was $66000.0, up 135.71% from the prior year.
- Capital Expenditures for Q1 2026 stood at $19000.0, down from $24000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $741000.0 in Q3 2023, with the low at -$916000.0 in Q4 2022.
- The 5-year median for Capital Expenditures is $16500.0 (2024), against an average of -$106500.0.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures tumbled 5188.89% in 2022, then soared 335.88% in 2023.
- Assembly Biosciences' Capital Expenditures stood at -$916000.0 in 2022, then increased by 16.92% to -$761000.0 in 2023, then jumped by 101.84% to $14000.0 in 2024, then soared by 71.43% to $24000.0 in 2025, then declined by 20.83% to $19000.0 in 2026.
- Business Quant data shows ASMB's Capital Expenditures at $19000.0 in Q1 2026, $24000.0 in Q4 2025, and $42000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | 102,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102,000.00 |
| Jun 30, 2026 | 102,000.00 |
| Mar 31, 2026 | 19,000.00 |
| Mar 31, 2026 | 19,000.00 |
| Dec 31, 2025 | 24,000.00 |
| Dec 31, 2025 | 24,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Dec 31, 2023 | -761,000.00 |
| Dec 31, 2023 | -761,000.00 |
| Sep 30, 2023 | 741,000.00 |
| Sep 30, 2023 | 741,000.00 |
| Jun 30, 2023 | -557,000.00 |
| Jun 30, 2023 | -557,000.00 |
| Dec 31, 2022 | -916,000.00 |
| Dec 31, 2022 | -916,000.00 |